Endocrine Abstracts

Introduction: Nowadays, use of chemotherapy in well-differentiated non medullary thyroid cancer, locally advanced stage and/or with radioiodine-refractory metastases is considered of scanty value. However, in the last 40 years was not published any phase III study nor a systematic review of its use in clinical setting.Methods: A systematic literature search was performed in databases such as Medline and Embase, among others. Two independent reviewers ana...

Introduction: Everolimus is a drug selective inhibitor of mTOR. In 2012 a Phase 2 study* of everolimus monotherapy demonstrated modest efficacy in patients with pheochromocytomas/paragangliomas. Our objective was to evaluate the efficacy and safety of everolimus in a patient with paraganglioma. (*Phase 2 study of everolimus monotherapy in patient with nonfunctioning neuroendocrine tumor or pheochromocytomas/paraglangliomas. Do-Young Oh et al. Cancer 2012 <str...